Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

06/01/2021 | 04:39pm EDT

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 25, 2021, Adamis Pharmaceuticals Corporation (the "Company") received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("NASDAQ") notifying the Company that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Filing" or the "Form 10-Q"), the Company is no longer in compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the "SEC").

The Notice also indicated that the Company has 60 calendar days to submit a plan to regain compliance and, if NASDAQ accepts the plan, NASDAQ can grant an exception of up to 180 calendar days from the Filing's due date to regain compliance. The Company may regain compliance at any time during this 180-day period upon filing with the SEC its Form 10-Q, as well as all subsequent required periodic financial reports that are due within that period. If NASDAQ does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a NASDAQ Hearings Panel. The Notice was issued in accordance with standard NASDAQ procedures and has no immediate effect on the listing of the Company's common stock on the NASDAQ Capital Market.

Item 7.01 Regulation FD Disclosure.

On May 28, 2021, the Company issued a press release disclosing the Company's receipt of the Notice. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Cautionary Note Regarding Forward-Looking Statements. This Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto may contain forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the note in the press release under the heading "Adamis Forward-Looking Statements."



Item 9.01  Financial Statements and Exhibits



Exhibit No.   Description

  99.1        Press Release, dated May 28, 2021

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses

All news about ADAMIS PHARMACEUTICALS CORPORATION
07/19ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holder..
AQ
07/19ADAMIS PHARMACEUTICALS : Announces Results of 2021 Annual Meeting of Stockholder..
BU
07/19Declaration of Voting Results by Adamis Pharmaceuticals
CI
07/14ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Boa..
AQ
07/13Adamis Pharmaceuticals Solicits Proxies from Shareholders
CI
07/13ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Boa..
BU
07/13ADAMIS PHARMACEUTICALS CORP : Regulation FD Disclosure, Financial Statements and..
AQ
07/02ADAMIS PHARMACEUTICALS : Sends Letter to Stockholders to Address Jerald A. Hamma..
AQ
07/01ADAMIS PHARMACEUTICALS :  Adamis Sends Letter to Stockholders to Address Jerald ..
BU
07/01Adamis Pharmaceuticals Solicits Proxies from Shareholders
CI
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,24x
Yield 2021 -
Capitalization 158 M 158 M -
Capi. / Sales 2021 7,17x
Capi. / Sales 2022 15,8x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,06 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
Robert O. Hopkins Chief Financial Officer & Secretary
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION118.51%183
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
ELI LILLY AND COMPANY41.25%209 276
NOVARTIS AG0.20%207 246